Krystal Biotech Files 8-K

Ticker: KRYS · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1711279

Krystal Biotech, Inc. 8-K Filing Summary
FieldDetail
CompanyKrystal Biotech, Inc. (KRYS)
Form Type8-K
Filed DateAug 28, 2024
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Krystal Biotech filed an 8-K, standard reporting, check exhibits for details.

AI Summary

Krystal Biotech, Inc. filed an 8-K on August 28, 2024, reporting on Regulation FD disclosures and financial statements/exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for the date.

Why It Matters

This filing indicates Krystal Biotech is meeting its regulatory reporting obligations. Investors should review the exhibits for any specific disclosures.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for reporting purposes and does not disclose any new material events or financial information.

Key Players & Entities

  • Krystal Biotech, Inc. (company) — Registrant
  • August 28, 2024 (date) — Date of Report
  • 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 (address) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits as of August 28, 2024.

What is Krystal Biotech, Inc.'s principal executive office address?

Krystal Biotech, Inc.'s principal executive offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania 15203.

What is the fiscal year end for Krystal Biotech, Inc.?

The fiscal year end for Krystal Biotech, Inc. is December 31.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Does this filing indicate any specific new material events?

No, this filing primarily serves as a current report for Regulation FD Disclosure and to file Financial Statements and Exhibits, without detailing specific new material events in the provided text.

Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-28 16:31:56

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 28, 2024, Jeune Aesthetics, Inc. (the "Company"), a wholly owned subsidiary of Krystal Biotech, Inc., issued a press release announcing phase 1 (PEARL-1) positive interim safety and efficacy results for KB301 in the treatment of lateral canthal lines and dynamic wrinkles of the dcollet. In addition, the press release indicated that the Company and Krystal Biotech, Inc. would host a conference call and webcast at 4:30 p.m. ET on August 28, 2024, to discuss the PEARL-1 Cohort 3 and Cohort 4 interim results, the KB301 clinical development program, the Company's pipeline product candidates, and the strategic vision for the Company. For purposes of the call and webcast, the Company provided a slide presentation, which is available on the "Investors" section of Krystal Biotech, Inc.'s website at www.krystalbio.com. Copies of the press release and the slide presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein. The information in this Item 7.01 of this Current Report on Form 8-K and in Exhibits 99.1 and 99.2 attached hereto shall not be (i) deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, or (ii) incorporated into any registration statement or other document filed with the Securities and Exchange Commission by Krystal Biotech, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 28, 2024 99.2 Slide Presentation dated August 2024 104 Cover Page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 28, 2024 KRYSTAL BIOTECH, INC. By: /s/ Krish S. Krishnan Name: Krish S. Krishnan Title: Chairman and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.